MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary
KEYWORDS: people, ttfm, flow, miraq, graft, coronary, hfus, technology, cardiac, surgery, study, miraq cardiac, cabg, artery, used

identified as relevant to this care pathway: • NICE's guideline on stable angina: management • NICE's guideline on acute coronary syndromes • European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines on myocardial revascularization. Population, setting and intended user The MiraQ cardiac TTFM and HFUS system is intended for use in people with coronary artery disease undergoing CABG surgery. The technology is used by cardiovascular surgeons, with nurses operating the system. It is used in tertiary care during cardiac surgery. The company states that both the surgeon and the operator of the MiraQ cardiac system need to be trained in using the system. The training is provided by the company and is included in the cost of the device. Costs Technology costs • MiraQ cardiac TTFM and HFUS system: £81,550 • unit cost L15 imaging probe: £8,365 • unit cost TTFM probe: £1,720 • annual maintenance costs (based on 10-year lifetime): £2,086. Costs of standard care Standard care is clinical assessment of graft flow using a variety of techniques, which are selected based on surgeon preference. These usually involve minimal or no extra cost. Resource consequences The company states that MiraQ cardiac with TTFM and HFUS
